Data presented by the FDA at the 2017 American Society of Clinical Oncology Annual Meeting identified a need for educating community-based oncology practices on testing for programmed death-ligand 1 (PD-L1) protein expression before patients diagnosed with metastatic non-small cell lung cancer (mNSCLC) are treated with nivolumab or pembrolizumab.
Data presented by the FDA at the 2017 American Society of Clinical Oncology Annual Meeting identified a need for educating community-based oncology practices on testing for programmed death-ligand 1 (PD-L1) protein expression before patients diagnosed with metastatic non-small cell lung cancer (mNSCLC) are treated with nivolumab or pembrolizumab.
The FDA first approved the programmed death-1 (PD-1) inhibitor nivolumab (Opdivo) for use in patients with squamous NSCLC who had progressed on platinum-based chemotherapy in March 2015, and in patients with non-squamous NSCLC in October 2015. Both approvals were independent of the expression of PD-L1. Pembrolizumab (Keytruda) was first approved for advanced NSCLC in October 2015 as well, but in patients whose tumors express PD-L1 and who had progressed on other treatments. The regulatory body approved the use of pembrolizumab in combination with a companion diagnostic, PD-L1 IHC 22C3 pharmDx test.
However, following these approvals, treatment patterns of nivolumab and pembrolizumab, as well as PD-L1 testing patterns, remained unclear. The FDA, therefore, conducted a retrospective analysis using de-identified patient-level electronic health record (EHR) data aggregated from community practices by Flatiron Health. Data were abstracted using both structured and unstructured EHR content with 10% duplicate abstraction to confirm data quality.
Patients with clinically-confirmed mNSCLC, diagnosed between January 2011 and March 2016, who had a documented order of, or had been administered, either nivolumab or pembrolizumab, were included in the analyses. PD-L1 expression testing results were abstracted from unstructured data in EHRs.
The analysis found that within the first year of FDA approval, 1351 patients with mNSCLC received nivolumab (96.7%), pembrolizumab (3.6%), or both drugs in different lines (0.3%). The median duration of treatment was 113 days (95% CI, 99 to 128 days).
Overall, 11.3% of patients were tested for PD-L1 expression, 42.2% of whom tested positive. PD-L1 expression testing increased quarterly (Q) from 3.0% in Q2 2015 to 12.8% in Q1 2016. An FDA-approved companion diagnostic was used 30.5% of the time. Among patients who received nivolumab, 93.5% were not tested for PD-L1 expression, 2.5% tested positive, and 2.8% tested negative for PD-L1. Among patients who received P, 37.5% were not tested for PD-L1 expression, 52.0% tested positive, and none tested negative.
Based on their results, the authors conclude point out the low rates of PD-L1 expression testing in community oncology practices for patients with mNSCLC receiving nivolumab or pembrolizumab. Testing rates increased quarterly following the approval of pembrolizumab, which was approved in tandem with a companion diagnostic. A majority of patients, the study found, were not tested using the FDA-approved companion diagnostic. Most patients who were not tested for PD-L1 expression or tested negative received nivolumab.
The study authors concluded that the real-world treatment patterns evaluated here underscore the importance of clinician education as data on optimal PD-L1 testing strategies guiding immunotherapy treatment decisions accumulates. Ongoing studies are collecting information that would help establish the impact of PD-L1 testing strategy on patient outcomes.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More